First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

S. Buti, M. Bersanelli, F. Maines, G. Facchini, F. Gelsomino, F. Zustovich, M. Santoni, E. Verri, U. De Giorgi, C. Masini, F. Morelli, M.G. Vitale, T. Sava, G. Prati, C. Librici, A.P. Fraccon, G. Fornarini, M. Maruzzo, F. Leonardi, O. Caffo

Research output: Contribution to journalArticlepeer-review

Abstract

Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.
Original languageEnglish
Pages (from-to)e609-e614
JournalClinical Genitourinary Cancer
Volume15
Issue number4
DOIs
Publication statusPublished - 2017

Keywords

  • Chromophobe RCC
  • First-line treatment
  • nccRCC
  • Papillary RCC
  • Pazopanib

Fingerprint Dive into the research topics of 'First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study'. Together they form a unique fingerprint.

Cite this